AliveX VP of Strategic Partnerships Dr. Robin Chan published 2 articles in neuroimmune top journals
In February, 2022, AliveX VP of Strategic Partnerships Dr. Robin Chan, and Professor Zhang Jing from Zhejiang University School of Medicine and First Affiliated Hospital, Professor Yang Ying from Peking University Department of Pathology published 2 co-authored articles seperately in Journal of Neuroinflammation (Impact Factor: 8.32) and GLIA (Impact Factor: 7.45).
In α-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinson's disease, Liu et al studies higher levels of peripheral monocytes, an important feature of Parkinson's disease (PD) pathogenesis. This study provided new insight into how hyperactivation of monocytes occurs in PD patients, and identified the central role played by α-syn-containing RBC-EVs in this process. In Astrocytic VEGFA: An essential mediator in blood-brain-barrier disruption in Parkinson's disease, Lan et al studies the roles of α-synuclein (α-syn) in BBB disruption, and concluded that oligomeric α-syn is critically involved in PD-associated BBB disruption, in a process that is mediated by astrocyte-derived VEGFA. Both studies provide important reference for further exploration of Parkinson's disease (PD) pathogenesis. Meanwhile, considering the similarities between neurodegenerative diseases, including protein congregation irregularity, lysosomes dysfunction and Immune system dysfunction, these two articles also provide significant reference for neurological diseases' R&D and translational studies.
Read more: Liu et al; Lan et al
More than the sum
of its parts
contact@alivexbiotech.com
Zeunerstrasse 9, 8037 Zurich
